This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Liewluck T, Kao JC, Mauermann ML. PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies. J Immunother. 2018 May;41(4):208–11.LiewluckTKaoJCMauermannML.PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies.2018May;41(4):208–11.10.1097/CJI.000000000000019629200081Search in Google Scholar
March KL, Samarin MJ, Sodhi A, Owens RE. Pembrolizumab-induced myasthenia gravis: A fatal case report. J Oncol Pharm Pr. 2018 Mar;24(2):146–9.MarchKLSamarinMJSodhiAOwensRE.Pembrolizumab-induced myasthenia gravis: A fatal case report.2018Mar;24(2):146–9.10.1177/107815521668738928147928Search in Google Scholar
Reynolds KL, Guidon AC. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist. 2019 Apr;24(4):435–43.ReynoldsKLGuidonAC.Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.2019Apr;24(4):435–43.10.1634/theoncologist.2018-0359645924030482825Search in Google Scholar
Erkilinc B, Karagozlu E, Uludag B. S52. A case of myasthenia gravis related to use of pembrolizumab. Clin Neurophysiol. 2018 May 1;129:e161.ErkilincBKaragozluEUludagB.S52. A case of myasthenia gravis related to use of pembrolizumab.2018May1;129:e161.10.1016/j.clinph.2018.04.412Search in Google Scholar
Hibino M, Maeda K, Horiuchi S, Fukuda M, Kondo T. Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer. Respirol Case Rep. 2018 Oct;6 (7):e00355.HibinoMMaedaKHoriuchiSFukudaMKondoT.Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer.2018Oct;6(7):e00355.10.1002/rcr2.355607993230094028Search in Google Scholar
Huh SY, Shin SH, Kim MK, Lee SY, Son KH, Shin HY. Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer. J Clin Neurol. 2018 Jan;14(1):115–7.HuhSYShinSHKimMKLeeSYSonKHShinHY.Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer.2018Jan;14(1):115–7.10.3988/jcn.2018.14.1.115576524629629546Search in Google Scholar
Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107(7):1055–KimuraTFukushimaSMiyashitaAAoiJJinninMKosakaT, et al.Myasthenic crisis and polymyositis induced by one dose of nivolumab.2016;107(7):1055–10.1111/cas.12961494672227420474Search in Google Scholar
Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, Gregory W, et al. Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. Oncologist. 2018 Aug;23(8):874–8.NeilanTGRothenbergMLAmiri-KordestaniLSullivanRJSteingartRMGregoryW, et al.Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.2018Aug;23(8):874–8.10.1634/theoncologist.2018-0157615618729802220Search in Google Scholar
Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017 Sep 12;89(11):1127–34.SuzukiSIshikawaNKonoedaFSekiNFukushimaSTakahashiK, et al.Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.2017Sep12;89(11):1127–34.10.1212/WNL.000000000000435928821685Search in Google Scholar
Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, et al. Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia GravisHeart and Skeletal Muscle Targeting in Myasthenia Gravis. JAMA Neurol. 2009;66(11):1334–8.SuzukiSUtsugisawaKYoshikawaHMotomuraMMatsubaraSYokoyamaK, et al.Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia GravisHeart and Skeletal Muscle Targeting in Myasthenia Gravis.2009;66(11):1334–8.Search in Google Scholar
Yokoyama S, Miyoshi H. Thymic tumors and immune checkpoint inhibitors. J Thorac Dis. 2018 May;10(Suppl 13):S1509-s1515.YokoyamaSMiyoshiH.Thymic tumors and immune checkpoint inhibitors.2018May;10(Suppl 13):S1509-s1515.10.21037/jtd.2017.10.157599450329951302Search in Google Scholar
Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, et al. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. J Clin Oncol. 2018 Jun 15;Jco2017773184.ChoJKimHSKuBMChoiYLCristescuRHanJ, et al.Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.2018Jun15;Jco2017773184.10.1200/JCO.2017.77.318429906252Search in Google Scholar
Mygland Å, Vincent A, Newsom-Davis J, Kaminski H, Zorzato F, Agius M, et al. Autoantibodies in Thymoma-Associated Myasthenia Gravis With Myositis or Neuromyotonia. JAMA Neurol. 2000;57(4):527–31.MyglandÅVincentANewsom-DavisJKaminskiHZorzatoFAgiusM, et al.Autoantibodies in Thymoma-Associated Myasthenia Gravis With Myositis or Neuromyotonia.2000;57(4):527–31.10.1001/archneur.57.4.52710768628Search in Google Scholar
Merveilleux du Vignaux C, Maury JM, Girard N. Novel Agents in the Treatment of Thymic Malignancies. Curr Treat Options Oncol. 2017 Aug 10;18(9):52.Merveilleux du VignauxCMauryJMGirardN.Novel Agents in the Treatment of Thymic Malignancies.2017Aug10;18(9):52.10.1007/s11864-017-0495-828795288Search in Google Scholar
Weissferdt A, Fujimoto J, Kalhor N, Rodriguez J, Bassett R, Wistuba I, et al. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 2017 Jun;30 (6):826–33.WeissferdtAFujimotoJKalhorNRodriguezJBassettRWistubaI, et al.Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.2017Jun;30(6):826–33.10.1038/modpathol.2017.628281549Search in Google Scholar
Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer. 2015 May;88 (2):154–9.KatsuyaYFujitaYHorinouchiHOheYWatanabeSTsutaK.Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.2015May;88(2):154–9.10.1016/j.lungcan.2015.03.00325799277Search in Google Scholar
Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, et al. Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors. J Thorac Oncol. 2015 Mar 1;10 (3):500–8.PaddaSKRiessJWSchwartzEJTianLKohrtHENealJW, et al.Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors.2015Mar1;10(3):500–8.10.1097/JTO.0000000000000429472025725402569Search in Google Scholar
Topakian R, Zimprich F, Iglseder S, Embacher N, Guger M, Stieglbauer K, et al. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol. 2019 Mar 1;266(3):699– 706.TopakianRZimprichFIglsederSEmbacherNGugerMStieglbauerK, et al.High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.2019Mar1;266(3):699–706.10.1007/s00415-019-09191-630649616Search in Google Scholar
Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, et al. RituximabCruszSMRadunovicA,ShepherdS,ShahS,NeweyV,PhillipsM,et al.Search in Google Scholar